Regencell Bioscience Holdings (RGC) Notes Payables (2021 - 2025)

Regencell Bioscience Holdings has reported Notes Payables for 5 years, with the latest figure at $106.0 in Q4 2025.

• For the quarter ending Q4 2025, Notes Payables changed N/A year-over-year to $106.0; the trailing twelve-month figure through Dec 2025 stood at $106.0 (changed N/A YoY), and the FY2025 full-year result was $2539.0, down 69.93% from the prior year.
• Notes Payables for Q4 2025 stood at $106.0, down from $2539.0 in the prior quarter.
• The five-year high for Notes Payables was $3.2 million in Q2 2021, with the low at $106.0 in Q4 2025.
• Historically, Notes Payables has averaged $547884.7 across 5 years, with a median of $9506.5 in 2023.
• Annual changes were most pronounced in 2022 — Notes Payables sank 99.52% — and 2024, when it fell 20.12%.
• Regencell Bioscience Holdings' Notes Payables stood at $3.2 million in 2021, then tumbled by 99.52% to $15650.0 in 2022, then sank by 32.46% to $10570.0 in 2023, then slipped by 20.12% to $8443.0 in 2024, then plunged by 98.74% to $106.0 in 2025.
• The last three Notes Payables figures came in at $106.0 (Q4 2025), $2539.0 (Q2 2025), and $8443.0 (Q2 2024), per Business Quant data.